<SEC-DOCUMENT>0000950103-21-008426.txt : 20210604
<SEC-HEADER>0000950103-21-008426.hdr.sgml : 20210604
<ACCEPTANCE-DATETIME>20210604140454
ACCESSION NUMBER:		0000950103-21-008426
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210604
FILED AS OF DATE:		20210604
DATE AS OF CHANGE:		20210604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		21995912

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp152315_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">




<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER <BR>
THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of June 2021.</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 15%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39071</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Biop&ocirc;le</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Route de la Corniche 3B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1066 Epalinges</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Switzerland</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 10pt">&#9746;</FONT></P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; width: 14%"><FONT STYLE="font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: June 4, 2021</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President &amp; General Counsel</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 2pt; font-size: 10pt; width: 15%; padding-left: 2pt"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="padding-right: 2pt; font-size: 10pt; width: 85%; padding-left: 2pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-right: 2pt; font-size: 10pt; padding-left: 2pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-right: 2pt; font-size: 10pt; padding-left: 2pt"><FONT STYLE="font-size: 10pt">Press release dated June 4, 2021</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp152315_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Arial, Helvetica, Sans-Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="image_001.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics
Presents Updated Clinical Data<BR>
at 2021 ASCO Annual Meeting</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>ZYNLONTA&trade;
LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory
DLBCL</I></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>Subgroup analyses
include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients
older than 65</I></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LAUSANNE, Switzerland,
June 4, 2021</B> &ndash; ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel
antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated clinical data from the
ZYNLONTA&trade; (loncastuximab tesirine-lpyl) Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma
(DLBCL) were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually June 4-8,
2021.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;The maturing
duration of response from the ZYNLONTA Phase 2 trial reported at ASCO reflects the strong data set that served as the basis of the accelerated
FDA approval in April,&rdquo; said Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer of ADC Therapeutics. &ldquo;We
are especially encouraged to see this positive trend continue to strengthen in a heavily pre-treated patient population, including patients
with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65.&rdquo;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In LOTIS-2, a single-arm,
open-label, 145-patient Phase 2 clinical trial in patients with relapsed or refractory DLBCL who had failed &ge;2 established therapies,
ZYNLONTA demonstrated continued substantial antitumor activity and an acceptable safety profile. Updated results, including analysis
of response in high-risk subgroups, were presented in a poster (abstract number: 7546) by Paolo F. Caimi, MD, University Hospitals Cleveland
Medical Center and Case Comprehensive Cancer Center, Case Western Reserve University.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Key data at the
March 1, 2021 data cut include:</U></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Overall
                                            response rate (ORR) was 48.3% and complete response rate (CRR) was 24.8%</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Median
                                            duration of response (mDoR) of 13.4 months for the 70 responders</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Median
                                            duration of response not reached for patients with a complete response</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Durable
                                            responses in high-risk patient groups, including:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Patients
                                            with double- / triple-hit or transformed DLBCL each had a median DoR not reached</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Patients
                                            with advanced stage disease (Stage III-IV) had a median DoR of 12.6 months</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Median
                                            DoR for older patients was longer than for younger patients (&ge;75 years, not reached; &ge;65
                                            years to &lt;75 years, 12.6 months; &lt;65 years, 9.3 months)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Patients
                                            with DLBCL refractory to first-line systemic therapy had a median DoR of 9.6 months compared
                                            with 12.6 months for patients who relapsed after responding to initial therapy</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No
                                            new safety concerns were identified during the study and no increase in toxicity was observed
                                            in patients aged &ge;65 years compared with patients &lt;65 years</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Two additional
posters presented at the 2021 ASCO Annual Meeting:</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Phase
                                            3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in
                                            patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5 (abstract
                                            number: TPS7574)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A
                                            Phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy
                                            in patients (pts) with advanced solid tumors (abstract number: 2556)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About ZYNLONTA&trade;
(loncastuximab tesirine-lpyl)</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ZYNLONTA&trade;
is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes
release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible
to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death. The U.S. Food and Drug Administration (FDA)
has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell
lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS),
DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. This indication is approved by the FDA under accelerated approval
based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical
benefit in a confirmatory trial.&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The FDA approval was based on data from LOTIS-2,
a large (n=145) Phase 2 multinational, single-arm clinical trial of ZYNLONTA for the treatment of adult patients with r/r DLBCL following
two or more prior lines of systemic therapy. The trial included a broad spectrum of heavily pre-treated patients &nbsp;(median three prior
lines of therapy) with&nbsp;very difficult to treat disease, including patients with high-grade B-cell lymphoma. The trial also enrolled
patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, and patients who had stem cell
transplants and CAR-T therapy prior to their treatment with ZYNLONTA. Results from the trial demonstrated an overall response rate (ORR)
of 48.3% (70/145 patients), which included a complete response (CR) rate of 24.1% (35/145 patients) and a partial response (PR) rate of
24.1% (35/145 patients). Patients had a median time to response of 1.3 months.&nbsp;At the most recent data cut-off for patients enrolled
in the trial,&nbsp;the median duration of response (mDoR)&nbsp;was 13.4 months.&nbsp;In a pooled safety population the most common adverse
reactions (&ge;20%) were thrombocytopenia, gamma-glutamyltransferase increased, neutropenia, anemia, hyperglycemia, transaminase elevation,
fatigue, hypoalbuminemia, rash, edema, nausea and musculoskeletal pain. In LOTIS-2, the most common (&ge;10%) grade &ge;3 treatment-emergent
adverse events were neutropenia (26.2%), thrombocytopenia (17.9%), gamma-glutamyltransferase increased (17.2%) and anemia (10.3%).&nbsp;</P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ZYNLONTA is being evaluated in combination
for earlier lines of therapy and as a monotherapy in other B-cell malignancies.&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About ADC Therapeutics</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics
(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody
drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients
with hematologic malignancies and solid tumors.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics&rsquo;
CD19-directed ADC ZYNLONTA&trade; (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse
large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with
other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Hodgkin lymphoma
and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, the Company has multiple PBD-based
ADCs in ongoing clinical and preclinical development.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ADC Therapeutics
is based in Lausanne (Biop&ocirc;le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,
please visit <FONT STYLE="color: Blue"><U>https://adctherapeutics.com/</U></FONT> and follow the Company on&nbsp;<FONT STYLE="color: Blue"><U>Twitter</U></FONT>&nbsp;and&nbsp;<FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ZYNLONTA&trade; is a trademark of ADC
Therapeutics SA.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CONTACTS:</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>Investors</B>&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Eugenia Litz&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADC Therapeutics&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Blue"><U>Eugenia.Litz@adctherapeutics.com</U></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">+44 7879 627205</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Amanda Hamilton&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">ADC Therapeutics&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt; color: Blue"><U>amanda.hamilton@adctherapeutics.com</U></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">+1 917-288-7023</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>EU Media</B>&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Alexandre M&uuml;ller&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Dynamics Group&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt; color: Blue"><U>amu@dynamicsgroup.ch</U></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">+41 (0) 43 268
3231</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>USA Media</B>&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">Annie Starr&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">6 Degrees&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt; color: Blue"><U>astarr@6degreespr.com</U></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">+1 973-768-2170</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" != *<# 2(  A$! Q$!_\0
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M2?\ $MM&(CQTD;N_]![?6NC#4'6G;IU,,165*%^I>?XR^(R[%(+%5).!Y;'
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M+I.+=1V9P8C.8QDE15UU_P" ?35%<?\ #_5=:U32V?4T#0)Q#.W#R?X@>O\
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MG;VK*%>*7,WMOOY_KV-JF&FWRJ/Q+3;R?Y=R\LEW=Q73)=>289Y%&V,-E1C
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@"A5>2^[!R3QTQZ45M0GSPNMOZ[F.)@X5.5Z/^NVA_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
